Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics
Mechanisms of action of anti-Aβ-antibodies. Anti-Aβ-antibodies can... | Download Scientific Diagram
Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre‐clinical AD, amnestic mild cognitive impairment and late‐stage AD - Tramutola - 2015 -
Blood‐based biomarkers for Alzheimer's disease | EMBO Molecular Medicine
Biomolecules | Free Full-Text | Microvascular Contributions to Alzheimer Disease Pathogenesis: Is Alzheimer Disease Primarily an Endotheliopathy?
Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer's disease | PNAS
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease - eBioMedicine
Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future | Signal Transduction and Targeted Therapy
JPM | Free Full-Text | Biomarkers for Alzheimer's Disease Early Diagnosis
Amyloid-β (Aβ) marker expression and Aβ aggregation in the... | Download Scientific Diagram
SARS-CoV-2 infection increases the gene expression profile for Alzheimer's disease risk: Molecular Therapy - Methods & Clinical Development
Advances in the development of new biomarkers for Alzheimer's disease | Translational Neurodegeneration | Full Text
New Alzheimer's Biomarkers may Support Early Diagnosis
Association of B cell profile and receptor repertoire with the progression of Alzheimer's disease - ScienceDirect
Isoorientin Affects Markers of Alzheimer's Disease via Effects on the Oral and Gut Microbiota in APP/PS1 Mice - The Journal of Nutrition
Decreased salivary lactoferrin levels are specific to Alzheimer's disease - eBioMedicine
Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia | ACS Chemical Neuroscience
JCM | Free Full-Text | Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review - ScienceDirect
Pyroglutamate Aβ cascade as drug target in Alzheimer's disease | Molecular Psychiatry
Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti-Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy | Nano Letters
IJMS | Free Full-Text | Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment
Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer's disease-like mouse model | Signal Transduction and Targeted Therapy
Frontiers | Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients
